Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Extemporaneous Compounding of Oral Acitretin Suspension for Pediatric Patient with Generalized Pustular Psoriasis

Author(s):  Choo Winnie

Issue:  Jan/Feb 2016 - Volume 20, Number 1
View All Articles in Issue

Page(s):  6-10

Extemporaneous Compounding of Oral Acitretin Suspension for Pediatric Patient with Generalized Pustular Psoriasis Page 1
Extemporaneous Compounding of Oral Acitretin Suspension for Pediatric Patient with Generalized Pustular Psoriasis Page 2
Extemporaneous Compounding of Oral Acitretin Suspension for Pediatric Patient with Generalized Pustular Psoriasis Page 3
Extemporaneous Compounding of Oral Acitretin Suspension for Pediatric Patient with Generalized Pustular Psoriasis Page 4
Extemporaneous Compounding of Oral Acitretin Suspension for Pediatric Patient with Generalized Pustular Psoriasis Page 5

Download in electronic PDF format for $75

Abstract:  Generalized pustular psoriasis is rare in children, but it can occur and affect an extensive body surface area of a child. Treatment regimens can include medications that are not available in pediatric dosage form. Acitretin is considered one of the treatment options for acute generalized pustular psoriasis in children, but, in Singapore, it is only available as Neotigason capsules. Extemporaneous compounding of the powder content in the capsules was developed for formulating the oral acitretin suspension with a standardized formulation table and compounding process at National Skin Centre. An appropriate beyond-use date of the extemporaneous preparation was assigned after reviewing the photostability data of acitretin, compatibility of the active ingredient and excipients, and United States Pharmacopeia <795> guidelines. It is deemed appropriate to assign a beyond-use date of 14 days when the extemporaneous preparation is stored in amber glass bottles at 2°C to 8°C.

Related Keywords: generalized pustular psoriasis, children, infants, inflammatory skin disorder, immune-mediated skin disorder, Singapore, acitretin, oral suspension, case report, photostability, Neotigason, compatibility, beyond-use date

Related Categories: DERMATOLOGY, PEDIATRICS, STABILITIES, COMPATIBILITIES, CASE REPORTS, ALLERGY/IMMUNOLOGY/INFLAMMATION, DOSAGE FORMS/DRUG CARRIERS

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Extemporaneous Compounding of Oral Acitretin Suspension for Pediatric Patient with Generalized Pustular Psoriasis
Choo Winnie
Jan/Feb 2016
Pg. 6-10

Skin Disorders in Horses; Case Report: Tripelennamine in the Treatment of Skin Disorders in Horses
Williams LaVonn A
, Fokken Dawn
Sep/Oct 2009
Pg. 386-389

Pediatric Compounding: Coloring Outside the Lines
Preckshot John
Jan/Feb 2001
Pg. 6-8

Management of Psoriasis with a XemaTop Topical Compounded Formula: A Case Report
Jones Nat
, Carvalho Maria, Branvold-Herr Andrea
May/Jun 2017
Pg. 205-211

Extemporaneous Indomethacin Oral Suspension Prepared from Injectable Ampules for Therapy in Premature Infants and Pediatric Patients
de Lafuente Yanina
, García Mónica Cristina, Jiminez-Kairuz Alvaro
Jul/Aug 2019
Pg. 324-331

Basics of Compounding for Dry-Skin Conditions
Allen Loyd V Jr
Nov/Dec 2003
Pg. 460-463

View Sample
Basics of Compounding for Disorders of the External Ear
Allen Loyd V Jr
Jan/Feb 2004
Pg. 46-48

Stability Issues for Compounding Extemporaneously Prepared Oral Formulations for Pediatric Patients
Schotik Debora
Jan/Feb 2001
Pg. 9-12

Extended Stability of Morphine and Sildenafil for Oral Use in Infants and Young Children
Nahata Milap C
May/Jun 2016
Pg. 247-249

Development of Extemporaneously Compounded Aripiprazole Oral Suspensions for Use in Children
Pramann Lance A
, Davidow Lawrence W, van Haandel Leon, Funk Ryan S
May/Jun 2016
Pg. 257-261

Novel Approaches to Topical Psoriasis Therapy
Koyama Gregory
, Liu Jenny, Scaffidi Alyse, Khazraee Maryam, Epstein Benjamin
Sep/Oct 2015
Pg. 357-365

Treatment Options for Psoriasis
Williams LaVonn A
, Humphreys Erica
May/Jun 2011
Pg. 204-213

Levetiracetam 50 mg/mL in Ora-Sweet and Ora-Plus Suspension
Allen Loyd V Jr
Nov/Dec 2021
Pg. 502

Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride
Alexander Kenneth S
, Thyangarajapuram N
Sep/Oct 2003
Pg. 389-393

In Vitro Skin Penetration and Skin Content of Progesterone from Various Topical Formulations
Heustess Allie
, Asbill Scott, Eagerton David, Arnold John
Nov/Dec 2014
Pg. 512-515

Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4
Espana B
, Joseph-Tornabène F, Jaquet Cécile, Perrot S, Prouillac C
Jul/Aug 2020
Pg. 327-336

Compounding for the Pediatric Patient
Allen Loyd V Jr
Mar/Apr 1997
Pg. 84-86

Evaluation of the Efficacy and Stability of Compounded Pentoxifylline-containing XemaTop for Psoriasis
Song Guiyun
, Ip Kendice, Shan Ashley, Banov Daniel, Bassani August S
Jul/Aug 2020
Pg. 337-345

Compounded Low-dose Naltrexone for the Treatment of Guttate Psoriasis: A Case Report
Muller George
, Grieshaber Robert, Talley J Floyd, Riepl Mike, Fellows Don
Jul/Aug 2018
Pg. 270-278

Women's Oral Health: Is There a Hormonal Link?
Preckshot John
Jan/Feb 2004
Pg. 10-14

Return to Top